Helix BioPharma Corp (HBP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Helix BioPharma Corp (HBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012205
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. The company develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company’s proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company’s proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp (HBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 11
Helix BioPharma to Enter into Agreement with ProMab Biotech 12
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 13
Licensing Agreements 14
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 14
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 15
Helix Polska Enters into Licensing Agreement with Helix BioPharma 16
Equity Offering 17
Helix BioPharma Raises USD3 Million in Private Placement of Units 17
Helix BioPharma Raises USD1 Million in Private Placement of Units 18
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 19
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 20
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 21
Helix BioPharma Raises USD1 Million in Private Placement of Units 22
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 23
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 24
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 25
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 26
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 27
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 28
Helix BioPharma Completes Private Placement Of Units For US$4.03 Million 29
Asset Transactions 30
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 30
Helix BioPharma Corp – Key Competitors 32
Helix BioPharma Corp – Key Employees 33
Helix BioPharma Corp – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 35
Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 37
Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 39
Dec 13, 2016: Helix BioPharma Announces Fiscal First Quarter 2017 Results 40
Oct 31, 2016: Helix BioPharma Announces Fiscal 2016 Results 41
Jun 14, 2016: Helix BioPharma Announces Third Quarter Fiscal 2016 Results 42
Mar 16, 2016: Helix Biopharma Announces Second Quarter Fiscal 2016 Results 43
Corporate Communications 44
Dec 01, 2017: Helix BioPharma Announces Management Change 44
Jul 17, 2017: Helix BioPharma Director Resigns 45
Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 46
Sep 07, 2016: Helix BioPharma Announces New Director Appointment 47
Apr 20, 2016: Helix BioPharma Announces Important Additions to Its Leadership Team 48
Mar 29, 2016: Helix BioPharma Announces CEO Change 49
Feb 04, 2016: Changes in the Leadership of Helix Polska 50
Jan 29, 2016: Helix BioPharma Announces Appointment of New Directors to the Board of Directors 51
Jan 12, 2016: Helix BioPharma Announces Appointment of Permanent New CEO and Changes at Board Level 52
Product News 53
10/19/2016: Helix BioPharma Announces CAR-T Poster Presentation at the AACR Conference on Tumor Immunology and Immunotherapy 53
07/21/2016: Helix BioPharma, Subsidiary, Helix Polska, Finalizes Grant Funding With the Polish National Center for Research and Development 54
05/09/2016: Helix BioPharma Subsidiary, Helix Polska Qualifies for CAD4.1 Million Grant From the Polish National Center for Research and Development 55
Other Significant Developments 56
Jun 02, 2016: Helix BioPharma Appoints Evolution Life Science Partners as Advisors 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Helix BioPharma Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 11
Helix BioPharma to Enter into Agreement with ProMab Biotech 12
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 13
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 14
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 15
Helix Polska Enters into Licensing Agreement with Helix BioPharma 16
Helix BioPharma Raises USD3 Million in Private Placement of Units 17
Helix BioPharma Raises USD1 Million in Private Placement of Units 18
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 19
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 20
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 21
Helix BioPharma Raises USD1 Million in Private Placement of Units 22
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 23
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 24
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 25
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 26
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 27
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 28
Helix BioPharma Completes Private Placement Of Units For US$4.03 Million 29
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 30
Helix BioPharma Corp, Key Competitors 32
Helix BioPharma Corp, Key Employees 33
Helix BioPharma Corp, Subsidiaries 34

★海外企業調査レポート[Helix BioPharma Corp (HBP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Informa plc:企業の戦略・SWOT・財務情報
    Informa plc - Strategy, SWOT and Corporate Finance Report Summary Informa plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Wincor Nixdorf AG:企業の戦略・SWOT・財務情報
    Wincor Nixdorf AG - Strategy, SWOT and Corporate Finance Report Summary Wincor Nixdorf AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • EVN AG:発電所・企業SWOT分析
    EVN AG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives) …
  • Lincoln Electric System:企業の発電所・SWOT分析2018
    Lincoln Electric System - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Ajinomoto Co., Inc.:企業の戦略・SWOT・財務分析
    Ajinomoto Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Ajinomoto Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bonavista Energy Corp (BNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Bonavista Energy Corp (Bonavista) is an intermediate energy company, which acquires, explores for, develops and produces oil and natural gas from its assets in the provinces of Alberta, British Columbia and Saskatchewan. Its core operations are concentrated in the Glauconite and Falher plays …
  • Praj Industries Ltd (PRAJIND):企業の財務・戦略的SWOT分析
    Summary Praj Industries Ltd (Praj) is a process and project engineering company that manufactures, develops, and markets biodiesel and ethanol. The company offers solutions for beverage alcohol and bioethanol plant, brewery, water and wastewater treatment plant, critical process equipment and system …
  • Synlogic Inc (SYBX):製薬・医療:M&Aディール及び事業提携情報
    Summary Synlogic Inc (Synlogic), formerly TMC Therapeutics Inc is a clinical stage drug development company that develops novel class of living medicines for the treatment of rare and genetic metabolic diseases, by applying synthetic biology to probiotics. The company’s pipeline includes SYNB1020 a …
  • Procurri Corporation Limited (BVQ):企業の財務・戦略的SWOT分析
    Procurri Corporation Limited (BVQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • IDT Corp (IDT):企業の財務・戦略的SWOT分析
    Summary IDT Corp (IDT) is a telecommunication service provider that offers mobile application development and telecommunication services. The company provides prepaid communication and payment services and international voice termination through its retail and wholesale division. Its services includ …
  • Corby Spirit and Wine Limited:企業の戦略・SWOT・財務情報
    Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report Summary Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Advantest Corporation (6857):企業の財務・戦略的SWOT分析
    Advantest Corporation (6857) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Ingersoll-Rand plc:企業の戦略・SWOT・財務情報
    Ingersoll-Rand plc - Strategy, SWOT and Corporate Finance Report Summary Ingersoll-Rand plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Victorian WorkCover Authority:企業の戦略的SWOT分析
    Victorian WorkCover Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Miltenyi Biotec GmbH-医療機器分野:企業M&A・提携分析
    Summary Miltenyi Biotec GmbH (Miltenyi) is a biotechnology company which provides biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation and cell culture. The company's services include sample preparation, cell separation, flow cytometry, cell cultur …
  • Rohto Pharmaceutical Co Ltd (4527):企業の財務・戦略的SWOT分析
    Rohto Pharmaceutical Co Ltd (4527) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Endo International Plc (ENDP)-医療機器分野:企業M&A・提携分析
    Summary Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceutical products, generic pharmaceuticals and other products through its operating companies including Endo Pharmaceuticals, Paladin Labs, Par Pharmaceutical, …
  • Future Plc (FUTR):企業の財務・戦略的SWOT分析
    Summary Future Plc (Future) is a media company that offers media and digital business solutions various customers. The company offers its services in various areas such as technology, creative, photography and design, games, advertising and film and music. It provides licensing and syndication, expo …
  • Prologis, Inc.:企業のM&A・事業提携・投資動向
    Prologis, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prologis, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • United States Postal Service:企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆